Mesoblast shares dip then flip on $800,000 insider buy

The Mesoblast share price is resettling after a near-70% spike in December.

| More on:
A financial expert or broker looks worried as he checks out a graph showing market volatility.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Mesoblast Ltd (ASX: MSB) shares started Tuesday trading in the red before reversing direction amid news of a major company insider purchase.

The Mesoblast share price is $2.81, up 1.08% at the time of writing.

The ASX biotech share is outperforming the S&P/ASX All Ordinaries Index (ASX: XAO), which is up 0.36%.

What's been happening lately?

We have to remember that Mesoblast shares are resettling after a major price spike in late December.

Mesoblast surged 69.2% between 19 December and 2 January after the company announced the long-awaited approval from the United States Food and Drug Administration for its flagship drug, Ryoncil.

Mesoblast hit a four-year high of $3.37 per share on 2 January.

Ryoncil, or remestemcel-L, treats the devastating steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children aged two years and older.

It's a life-threatening condition with a high mortality rate.

Every year in the United States, approximately 10,000 patients undergo an allogeneic bone marrow
transplant. About 1,500 of them are children.

Approximately 50% develop aGvHD, and almost half of those do not respond to the current first-line treatment of steroids.

Mesoblast's astounding share price surge in December led to the biotech topping the 5 best ASX All Ords share list of 2024. Overall, Mesoblast stock skyrocketed by 900% last year.

Therefore, it's not surprising that the Mesoblast share price has corrected since December's extraordinary spike.

A $260 million global private placement completed last week to fund the launch of Ryoncil in the US has also driven Mesoblast shares lower.

This is usual, given a placement means new shares are put into the market, thereby diluting everyone else's stake in the company.

The placement had an offer price of $2.50 per new share. Mesoblast offered the new shares primarily to existing major shareholders in the United States, the United Kingdom and Australia.

The company did not offer an accompanying share purchase plan (SPP) to ordinary retail investors.

Insider takes advantage of weaker share price

The latest official news from Mesoblast is that executive director and chief medical officer Dr Eric Rose has invested more than half a million US dollars of his own money to further invest in the biotech.

Dr Rose acquired 30,310 American Depositary Shares (ADS) on-market on 16 January. Each ADS represents 10 ordinary Mesoblast shares.

He paid US$16.70 per ADS for a total consideration of US$506,214 (A$806,567).

Insider buys are usually inspiring and comforting for existing shareholders. They imply that the insider feels confident in the company's future.

This is a particularly helpful signal now, especially for Mesoblast shareholders who may be regretting not selling at the four-year peak (as if anyone could have picked it!) on 2 January.

Are Mesoblast shares a buy?

For now, John Athanasiou of Red Leaf Securities has a hold rating on Mesoblast shares.

He recommends that existing shareholders and potential investors wait until Ryoncil is commercialised in the US before buying more Mesoblast shares.

On The Bull, Athanasiou said:

Mesoblast is on track for another promising year as it nears commercialising Ryoncil.

We expect this development to boost revenue and market share.

However, given the impressive rally in MSB shares during 2024, we believe it's prudent to wait until Ryoncil is fully commercialised before making new investments.

Motley Fool contributor Bronwyn Allen has positions in Mesoblast. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man looking at his laptop and thinking.
Earnings Results

CSL shares push higher despite 'mixed result with headline misses'

There were positives and negatives in the company's first half performance.

Read more »

Scientists working in the laboratory and examining results.
Earnings Results

CSL share price on watch amid $2.1b half year profit and dividend hike

Let's see how this biotech giant performed during the first half of FY 2025.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 300 healthcare stock just rocketed 20% on BIG earnings growth

Investors are piling into the ASX 300 healthcare stock on Monday. But why?

Read more »

Health professional putting on gloves.
Earnings Results

Why this ASX 200 share is soaring in Monday's sinking market

The ASX 200 share is shrugging off the broader market fall today to rocket higher. But why?

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Why is the Sigma share price soaring 6%?

Sigma has upgraded its FY25 guidance ahead of the anticipated Chemist Warehouse merger completion.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Which ASX 200 healthcare share will pay the best dividend yield in 2025?

Earnings season is underway and dividend announcements are on investors' minds.

Read more »

A person is weighed down by a huge stack of coins, they have received a big dividend payout.
Dividend Investing

Looking to bag the record high ResMed dividend? You better hurry!

Unlike the majority of ASX 200 income stocks, ResMed pays dividends every quarter.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 reasons to buy CSL shares today

Two investment experts expect a big turnaround for CSL shares in 2025.

Read more »